pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Treatment of rapid cycling across practice guideline
| Guidelines | First-line treatment | Next-step intervention | Later intervention |
|---|---|---|---|
| KMAP-BP 2022 | · Currently manic: MS + AAP, Val, Li, QUE, ARI, OLA, RIS · Currently depressed: MS + AAP, QUE, ARI, Li, Val, OLA, AAP + LMT, MS + LMT |
· Currently manic: 2MSs. MS + LMT, AAP + LMT, MS + TAP, ECT · Currently depressed: LMT, 2MSs, MS + AAP + AD, MS + AD, MS + TAP, ECT |
· Currently manic: MS + AD · Currently depressed: AD |
| BAP 2016 | No recommendation | ||
| CANMAT 2018 | No recommendation | ||
| CINP-BD-2017 | ARI, QUE, Val | OLA, Li | MS + QUE (or RIS) |
| NICE 2014 | Same as with other types of bipolar disorder | ||
| RANZCP 2020 | No recommendation |
AAP, atypical antipsychotics; AD, antidepressant; ARI, aripiprazole; BAP 2016, The British Association for Psychopharmacology Guidelines for Treatment for Bipolar Disorder 2016; CANMAT 2018, Canadian Network for Mood and Anxiety Treatments 2018; CINP-BD 2017, The International College of Neuropsychopharmacology Treatment Guidelines for Bipolar Disorder 2017; ECT, electroconvulsive therapy; KMAPBP 2022, Korean Medication Algorithms for Bipolar Disorder 2022; Li, lithium; LMT, lamotrigine; MS, mood stabilizer; NICE 2014, National Institute for Health and Clinical Excellence Treatment for Bipolar Disorder; OLA, olanzapine; QUE, quetiapine; RANZCP 2020, The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders; RIS, risperidone; TAP, typical antipsychotics; Val, various kinds of valproic acids.